Long-term Effectiveness Study on Cholesterol-reducing Activity

October 26, 2016 updated by: Danone Japan

Clinical Study for Evaluating the Plasma Cholesterol-reducing Activity of a Plant Sterol-enriched Yoghurt Drink - Effectiveness and Long-term Safety Study

The purpose of this study is to investigate the effect of consumption of a drinkable low fat fermented milk enriched with 0,8g or 1,6g of plant sterols on reducing plasma cholesterol (LDL-cholesterol) concentration during 12 weeks of product consumption.

Study Overview

Study Type

Interventional

Enrollment (Actual)

138

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Osaka, Japan, 560-0082
        • Senrichuo Ekimae Clinic - Senri Life Science Center 13F

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Subject with total cholesterol plasma level between 200 mg/dL to 240 mg/dL; and LDL-cholesterol between 120 mg/dL to 160 mg/dL.
  2. Subject aged from 20 to 65 years (bounds included)
  3. Subject with BMI between 19 - 30 kg/m² (bounds included)
  4. Subject with triglycerides under 400 mg/dL (4.6 mmol/L)
  5. Non diabetic subjects (BS≤125 mg/dL)
  6. Non hypertensive subjects (SBP<140mmHg and DBP<90 mmHg)
  7. Subject accepting to follow the dietary recommendations advisable for hypercholesterolemic
  8. Subject agreeing not to consume any other plant sterol supplements or excess plant sterol during the study period
  9. Subject, upon briefing of the content of the present study, fully understanding and agreeing to its objective; and being able to personally sign a written informed consent and subject having signed the written consent to take part in the study

Exclusion Criteria:

  1. Subject currently involved in a clinical trial.
  2. Subject taking any dislipademia treatment (statins,ezetimibe, niacin, omega-3 FA, fibrates)
  3. Subject having blood sample of 200 ml or more taken (e.g., donated blood) within 1 month, or 400 ml or more within 3 months of the start of the present study.
  4. For female subject: pregnancy or intention to be pregnant during the study.
  5. For female subject: breast feeding.
  6. Subject presenting known allergy or history of hypersensitivity to plant sterols or dairy products.
  7. Subject having lactose intolerance.
  8. Subjects having sitosterolemia
  9. Diabetic subject (Type I and type II)
  10. Subject with heavy alcohol intake (>60g/day)
  11. Subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters
  12. Subject receiving a transplant or under immunosuppressor treatment
  13. Subject receiving treatment for serious liver, renal, cardio-vascular, respiratory, endocrine, or metabolic disorders.
  14. Subject having cardiovascular history or cardiovascular events (e.g.myocardial infarction, angina pectoris, surgical or endocoronary intervention, stroke, inferior member arteriopathy, etc.) during the last 6 months
  15. Subject deemed unsuitable by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1 = Tested product dose 1
1 = Intervention with test product 1 (0,8g of plant sterol/day)
Active Comparator: 2 = Tested product dose 2
2 = Intervention with test product 2 (1,6g of plant sterol/day)
Sham Comparator: 3 = Control product
3 = Intervention 3 (1 control product/day)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2010

Primary Completion (Actual)

July 1, 2010

Study Completion (Actual)

December 1, 2010

Study Registration Dates

First Submitted

January 26, 2012

First Submitted That Met QC Criteria

January 26, 2012

First Posted (Estimate)

January 30, 2012

Study Record Updates

Last Update Posted (Estimate)

October 27, 2016

Last Update Submitted That Met QC Criteria

October 26, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • NU332

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Normal and Mild Hypercholesterolemic Subjects

Clinical Trials on 1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).

3
Subscribe